Dr. Deya Corzo is an expert in drug development with over two decades of experience in the biopharma sector across various technology platforms, including therapeutic recombinant proteins, gene and cell therapy, and chemically-synthesized therapeutics.

She is CMO-in-residence at Roivant Sciences, based in NYC, and a Scientific Advisor to MiNA Therapeutics, based in London. Her industry experience includes prior roles as CMO at Sigilon Therapeutics and Sojournix Inc.; senior Medical Affairs positions at Celgene Corp. and Takeda Oncology; and senior R&D positions at uniQure and Genzyme Corp.

In the latter roles, Deya led the team responsible for the global development and approval of two blockbuster therapies, Myozyme™ and Lumizyme™ for Pompe disease. She also contributed significantly to the early development of Hemgenix™, the first gene therapy for Hemophilia B—treatments recognized with two prestigious awards, the US and UK Prix Galien, respectively.

Deya is a board-certified clinical geneticist and pediatrician. For over 20 years, she served as a faculty member at the Harvard Medical School/Boston Children's Hospital/Clinical Genetics Division, where she completed postdoctoral research and clinical training.